149 related articles for article (PubMed ID: 22354912)
41. Combined anti-CD40 and anti-IL-23 monoclonal antibody therapy effectively suppresses tumor growth and metastases.
von Scheidt B; Leung PS; Yong MC; Zhang Y; Towne JE; Smyth MJ; Teng MW
Cancer Res; 2014 May; 74(9):2412-21. PubMed ID: 24556719
[TBL] [Abstract][Full Text] [Related]
42. Effective Combination of Innate and Adaptive Immunotherapeutic Approaches in a Mouse Melanoma Model.
Rakhmilevich AL; Felder M; Lever L; Slowinski J; Rasmussen K; Hoefges A; Van De Voort TJ; Loibner H; Korman AJ; Gillies SD; Sondel PM
J Immunol; 2017 Feb; 198(4):1575-1584. PubMed ID: 28062694
[TBL] [Abstract][Full Text] [Related]
43. Augmented IL-15Rα expression by CD40 activation is critical in synergistic CD8 T cell-mediated antitumor activity of anti-CD40 antibody with IL-15 in TRAMP-C2 tumors in mice.
Zhang M; Ju W; Yao Z; Yu P; Wei BR; Simpson RM; Waitz R; Fassò M; Allison JP; Waldmann TA
J Immunol; 2012 Jun; 188(12):6156-64. PubMed ID: 22593619
[TBL] [Abstract][Full Text] [Related]
44. The human agonistic CD40 antibody ADC-1013 eradicates bladder tumors and generates T-cell-dependent tumor immunity.
Mangsbo SM; Broos S; Fletcher E; Veitonmäki N; Furebring C; Dahlén E; Norlén P; Lindstedt M; Tötterman TH; Ellmark P
Clin Cancer Res; 2015 Mar; 21(5):1115-26. PubMed ID: 25316820
[TBL] [Abstract][Full Text] [Related]
45. Locally delivered CD40 agonist antibody accumulates in secondary lymphoid organs and eradicates experimental disseminated bladder cancer.
Sandin LC; Orlova A; Gustafsson E; Ellmark P; Tolmachev V; Tötterman TH; Mangsbo SM
Cancer Immunol Res; 2014 Jan; 2(1):80-90. PubMed ID: 24778163
[TBL] [Abstract][Full Text] [Related]
46. A novel targeting therapy of malignant mesothelioma using anti-podoplanin antibody.
Abe S; Morita Y; Kaneko MK; Hanibuchi M; Tsujimoto Y; Goto H; Kakiuchi S; Aono Y; Huang J; Sato S; Kishuku M; Taniguchi Y; Azuma M; Kawazoe K; Sekido Y; Yano S; Akiyama S; Sone S; Minakuchi K; Kato Y; Nishioka Y
J Immunol; 2013 Jun; 190(12):6239-49. PubMed ID: 23690472
[TBL] [Abstract][Full Text] [Related]
47. IL-2/CD40-activated macrophages rescue age and tumor-induced T cell dysfunction in elderly mice.
Jackaman C; Dye DE; Nelson DJ
Age (Dordr); 2014 Jun; 36(3):9655. PubMed ID: 24744051
[TBL] [Abstract][Full Text] [Related]
48. Tumour eradication and induction of memory against murine mesothelioma by combined immunotherapy.
Kissick HT; Ireland DJ; Krishnan S; Madondo M; Beilharz MW
Immunol Cell Biol; 2012 Sep; 90(8):822-6. PubMed ID: 22349521
[TBL] [Abstract][Full Text] [Related]
49. Interleukin-15 combined with an anti-CD40 antibody provides enhanced therapeutic efficacy for murine models of colon cancer.
Zhang M; Yao Z; Dubois S; Ju W; Müller JR; Waldmann TA
Proc Natl Acad Sci U S A; 2009 May; 106(18):7513-8. PubMed ID: 19383782
[TBL] [Abstract][Full Text] [Related]
50. Three agonist antibodies in combination with high-dose IL-2 eradicate orthotopic kidney cancer in mice.
Westwood JA; Darcy PK; Guru PM; Sharkey J; Pegram HJ; Amos SM; Smyth MJ; Kershaw MH
J Transl Med; 2010 Apr; 8():42. PubMed ID: 20426873
[TBL] [Abstract][Full Text] [Related]
51. Intratumoral treatment of smaller mouse neuroblastoma tumors with a recombinant protein consisting of IL-2 linked to the hu14.18 antibody increases intratumoral CD8+ T and NK cells and improves survival.
Yang RK; Kalogriopoulos NA; Rakhmilevich AL; Ranheim EA; Seo S; Kim K; Alderson KL; Gan J; Reisfeld RA; Gillies SD; Hank JA; Sondel PM
Cancer Immunol Immunother; 2013 Aug; 62(8):1303-13. PubMed ID: 23661160
[TBL] [Abstract][Full Text] [Related]
52. In vivo anti-tumor activity of combinations of interferon alpha and interleukin-2 in a murine model. Correlation of efficacy with the induction of cytotoxic cells resembling natural killer cells.
Brunda MJ; Bellantoni D; Sulich V
Int J Cancer; 1987 Sep; 40(3):365-71. PubMed ID: 3497883
[TBL] [Abstract][Full Text] [Related]
53. NK cells from pleural effusions are potent antitumor effector cells.
Terme M; Fridman WH; Tartour E
Eur J Immunol; 2013 Feb; 43(2):331-4. PubMed ID: 23322344
[TBL] [Abstract][Full Text] [Related]
54. Natural killer cells play an essential role in resolution of antigen-induced inflammation in mice.
Anuforo OUU; Bjarnarson SP; Jonasdottir HS; Giera M; Hardardottir I; Freysdottir J
Mol Immunol; 2018 Jan; 93():1-8. PubMed ID: 29112834
[TBL] [Abstract][Full Text] [Related]
55. A very long-acting IL-15: implications for the immunotherapy of cancer.
Hangasky JA; Chen W; Dubois SP; Daenthanasanmak A; Müller JR; Reid R; Waldmann TA; Santi DV
J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35101947
[TBL] [Abstract][Full Text] [Related]
56. Regression of established AB1 murine mesothelioma induced by peritumoral injections of CpG oligodeoxynucleotide either alone or in combination with poly(I:C) and CD40 ligand plasmid DNA.
Stone GW; Barzee S; Snarsky V; Santucci C; Tran B; Kornbluth RS
J Thorac Oncol; 2009 Jul; 4(7):802-8. PubMed ID: 19550243
[TBL] [Abstract][Full Text] [Related]
57. Successful combined intratumoral immunotherapy of established murine mesotheliomas requires B-cell involvement.
Krishnan S; Bakker E; Lee C; Kissick HT; Ireland DJ; Beilharz MW
J Interferon Cytokine Res; 2015 Feb; 35(2):100-7. PubMed ID: 25259549
[TBL] [Abstract][Full Text] [Related]
58. Vascular targeting of anti-CD40 antibodies and IL-2 into autochthonous tumors enhances immunotherapy in mice.
Hamzah J; Nelson D; Moldenhauer G; Arnold B; Hämmerling GJ; Ganss R
J Clin Invest; 2008 May; 118(5):1691-9. PubMed ID: 18398504
[TBL] [Abstract][Full Text] [Related]
59. The STING agonist, DMXAA, reduces tumor vessels and enhances mesothelioma tumor antigen presentation yet blunts cytotoxic T cell function in a murine model.
Graham PT; Nowak AK; Cornwall SMJ; Larma I; Nelson DJ
Front Immunol; 2022; 13():969678. PubMed ID: 36466911
[TBL] [Abstract][Full Text] [Related]
60. Polymeric microparticles for sustained and local delivery of antiCD40 and antiCTLA-4 in immunotherapy of cancer.
Rahimian S; Fransen MF; Kleinovink JW; Amidi M; Ossendorp F; Hennink WE
Biomaterials; 2015 Aug; 61():33-40. PubMed ID: 25993015
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
